Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Randomization and Treatment	STARTED	Capecitabine	109
Randomization and Treatment	STARTED	CDX-011	218
Randomization and Treatment	COMPLETED	Capecitabine	6
Randomization and Treatment	COMPLETED	CDX-011	15
Randomization and Treatment	NOT COMPLETED	Capecitabine	103
Randomization and Treatment	NOT COMPLETED	CDX-011	203
Survival Follow up	STARTED	Capecitabine	92
Survival Follow up	STARTED	CDX-011	213
Survival Follow up	COMPLETED	Capecitabine	76
Survival Follow up	COMPLETED	CDX-011	199
Survival Follow up	NOT COMPLETED	Capecitabine	16
Survival Follow up	NOT COMPLETED	CDX-011	14

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01997333/flow